T-2513

• UNSPSC Description:

  T-2513 is a selective topoisomerase I inhibitor. T-2513 binds covalently to and stabilizes the topoisomerase I-DNA complex and inhibits DNA replication and RNA synthesis, ultimately leading to cell death[1].

• Target Antigen:

  DNA/RNA Synthesis; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/t-2513.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(OCCCN)=CC=C5N=C4C3=C2)=O

• Molecular Weight:

  449.50

• References & Citations:

  [1]Stephan A Veltkamp, et al. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res. 2008 Nov 15;14(22):7535-44.|[2]S Okuno, et al. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  288247-87-0